Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24573583 | 1.00 | NPBWR1 (0.34) | NPBWR1EGFR | |
| SCHEMBL24573423 | 0.87 | AKT1 (0.32) | EGFR | |
| SCHEMBL30248878 | 0.87 | AKT1 (0.32) | EGFR | |
| SCHEMBL29735054 | 0.86 | AKT1 (0.34) | EGFR | |
| SCHEMBL24573625 | 0.86 | AKT1 (0.34) | EGFR | |
| SCHEMBL24573606 | 0.85 | NPBWR1 (0.37) | NPBWR1EGFR | |
| SCHEMBL24573580 | 0.83 | NPBWR1 (0.35) | NPBWR1 | |
| SCHEMBL30248975 | 0.82 | AOC3 (0.34) | NPBWR1EGFR | |
| SCHEMBL24573579 | 0.82 | AOC3 (0.34) | NPBWR1EGFR | |
| SCHEMBL24572776 | 0.82 | NPBWR1 (0.32) | NPBWR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885 |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.